Liver cirrhosis is characterized by hyperaccumulation of fibrous tissue components and iscommonly observed in latter or terminal states of chronic hepatic diseases. In this study, theantifibrotic effects of GLM001 on liver cirrhosis were examined in bile duct ligated rats andpatients with hepatic diseases. GLM001 (250 mg/kg rat weight/day) was administrated tocirrhotic rats for 4 weeks and to humans for 14 weeks. Bile duct ligated rats significantly increasedliver collagen content and biochemical markers of hepatic injury. Liver histology showed collagenfiber deposition was increased and the normal architecture was lost with large zones of necrosisbeing observed frequently. GLM001 administrated rats showed significantly decreased livercollagen content, and accumulation of collagen fiber in histological analysis. Patients, who weretreated with GLM001, showed decreases in biochemical markers of hepatic diseases. These resultsdemonstrate the usefulness of GLM001 as an antifibrotic agent for liver cirrhosis.